Related Experiment Video
Updated: Apr 7, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
Published on: January 22, 2019
Reactivation of latent HIV-1 provirus via targeting protein phosphatase-1
Mudit Tyagi1, Sergey Iordanskiy2, Tatyana Ammosova3,4,5
1Department of Medicine, The George Washington University, Washington, DC, 2003, USA. tmudit@email.gwu.edu.
Background:
HIV-1 escapes antiretroviral drugs by integrating into the host DNA and forming a latent transcriptionally silent HIV-1 provirus. This provirus presents the major hurdle in HIV-1 eradication and cure. Transcriptional activation, which is prerequisite for reactivation and the eradication of latent proviruses, is impaired in latently infected T cells due to the lack of host transcription factors, primarily NF-κB and P-TEFb (CDK9/cyclin T1). We and others previously showed that protein phosphatase-1 (PP1) regulates HIV-1 transcription by modulating CDK9 phosphorylation. Recently we have developed a panel of small molecular compounds targeting a non-catalytic site of PP1.
Results:
Here we generated a new class of sulfonamide-containing compounds that activated HIV-1 in acute and latently infected cells. Among the tested molecules, a small molecule activator of PP1 (SMAPP1) induced both HIV-1 replication and reactivation of latent HIV-1 in chronically infected cultured and primary cells. In vitro, SMAPP1 interacted with PP1 and increased PP1 activity toward a recombinant substrate. Treatment with SMAPP1 increased phosphorylation of CDK9's Ser90 and Thr186 residues, but not Ser175. Proteomic analysis showed upregulation of P-TEFb and PP1 related proteins, including PP1 regulatory subunit Sds22 in SMAPP1-treated T cells. Docking analysis identified a PP1 binding site for SMAPP1 located within the C-terminal binding pocket of PP1.
Conclusion:
We identified a novel class of PP1-targeting compounds that reactivate latent HIV-1 provirus by targeting PP1, increasing CDK9 phosphorylation and enhancing HIV transcription. This compound represents a novel candidate for anti-HIV-1 therapeutics aiming at eradication of latent HIV-1 reservoirs.
Insights
Researchers developed novel small molecules that reactivate latent HIV-1 by targeting protein phosphatase-1 (PP1), enhancing viral transcription and offering a potential cure for HIV.
Area of Science:
- Virology
- Molecular Biology
- Drug Discovery
Background:
- Human immunodeficiency virus type 1 (HIV-1) establishes latent reservoirs by integrating into host DNA, hindering eradication efforts.
- Reactivation of latent HIV-1 requires transcriptional activation, often impaired in infected cells due to low levels of transcription factors like P-TEFb (CDK9/cyclin T1).
- Protein phosphatase-1 (PP1) has been shown to regulate HIV-1 transcription by modulating CDK9 phosphorylation, and novel compounds targeting PP1 have been developed.
Purpose of the Study:
- To develop and evaluate a new class of small molecular compounds targeting a non-catalytic site of PP1 for HIV-1 reactivation.
- To investigate the mechanism by which these compounds reactivate latent HIV-1, focusing on PP1 activity and CDK9 phosphorylation.
Main Methods:
- Synthesis and testing of novel sulfonamide-containing compounds, including a specific small molecule activator of PP1 (SMAPP1).
- Assessing HIV-1 replication and latent reservoir reactivation in acutely and chronically infected cells (cultured and primary).
- In vitro assays to confirm SMAPP1 interaction with PP1 and its effect on PP1 activity, CDK9 phosphorylation, and protein expression via proteomic analysis. Docking analysis was used to identify the binding site.
Main Results:
- A novel class of sulfonamide compounds, including SMAPP1, demonstrated activation of HIV-1 in both acute and latent infections.
- SMAPP1 effectively reactivated latent HIV-1 in chronically infected cells and increased HIV-1 replication.
- SMAPP1 enhanced PP1 activity, increased phosphorylation of CDK9 at specific residues (Ser90 and Thr186), and led to the upregulation of PP1 and P-TEFb related proteins.
Conclusions:
- A novel class of PP1-targeting compounds, exemplified by SMAPP1, can reactivate latent HIV-1 provirus.
- These compounds work by enhancing PP1 activity, increasing CDK9 phosphorylation, and boosting HIV transcription.
- This discovery presents a promising new therapeutic strategy for eradicating latent HIV-1 reservoirs.
Related Concept Videos
Size and Structure of Viral Genomes
The JAK-STAT Signaling Pathway
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Retrovirus Life Cycles
Mechanisms of Retrovirus-induced Cancers

